Document Detail

Cholesterol lowering and the vessel wall: new insights and future perspectives.
MedLine Citation:
PMID:  11702850     Owner:  NLM     Status:  MEDLINE    
The basis for most acute coronary events is either rupture or fissuring of unstable atherosclerotic plaques with subsequent thrombosis leading to coronary artery occlusion. The development of atherosclerotic plaques takes several decades, but the mechanical features determining its stability and the risk of rupture can change very rapidly depending on a number of internal factors. Unstable plaques have a large lipid core, a thin overlying fibrous cap and an abundance of inflammatory cells. The most important factor determining the plaque stability is the plasma level of atherogenic LDL particles. Increased levels of these particles cause endothelial dysfunction with impaired vasodilatation capacity and prevalence of vasoconstriction, maintain inflammatory infiltration of the plaque, impair the strength of the fibrous cap and facilitate aggregation and coagulation. Effective lowering of plasma cholesterol by pharmacological and non-pharmacological means can revert most of these processes and increase the plaque's mechanical stability within several hours to days. Lipid lowering therapy can therefore decrease the risk of acute coronary events within a very short space of time. Thus a radical decrease in lipid levels, along with modification of other risk factors, may become the cornerstone for treatment of acute coronary syndromes, in addition to being an effective treatment in primary and secondary prevention of coronary heart disease (CHD).
T Stulc; R Ceska
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Physiological research / Academia Scientiarum Bohemoslovaca     Volume:  50     ISSN:  0862-8408     ISO Abbreviation:  Physiol Res     Publication Date:  2001  
Date Detail:
Created Date:  2001-11-12     Completed Date:  2002-04-17     Revised Date:  2008-04-02    
Medline Journal Info:
Nlm Unique ID:  9112413     Medline TA:  Physiol Res     Country:  Czech Republic    
Other Details:
Languages:  eng     Pagination:  461-71     Citation Subset:  IM    
Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticholesteremic Agents / therapeutic use
Antilipemic Agents / therapeutic use
Arteriosclerosis / pathology,  physiopathology,  prevention & control
Cholesterol / blood*
Coronary Disease / pathology,  physiopathology,  prevention & control
Coronary Vessels / pathology*,  physiopathology
Endothelium, Vascular / physiopathology
Lipoproteins, LDL / blood
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Antilipemic Agents; 0/Lipoproteins, LDL; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of leptin in human physiology and pathophysiology.
Next Document:  Nitric oxide synthase mRNA levels correlate with gene expression of angiotensin II type-1 but not ty...